Critical Role of SREBP-1c Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV Deficiency

Objective— APOA5 variants are strongly associated with hypertriglyceridemia, as well as increased risks of cardiovascular disease and acute pancreatitis. Hypertriglyceridemia in apo AV dysfunction often aggravates by environmental factors such as high-carbohydrate diets or aging. To date, the molecular mechanisms by which these environmental factors induce hypertriglyceridemia are poorly defined, leaving the high-risk hypertriglyceridemia condition undertreated. Previously, we reported that LXR (liver X receptor)-SREBP (sterol regulatory element-binding protein)-1c pathway regulates large-VLDL (very low-density lipoprotein) production induced by LXR agonist. However, the pathophysiological relevance of the finding remains unknown. Approach and Results— Here, we reconstitute the environment-induced hypertriglyceridemia phenotype of human APOA5 deficiency in Apoa5−/− mice and delineate the role of SREBP-1c in vivo by generating Apoa5−/−;Srebp-1c−/− mice. The Apoa5−/− mice, which showed moderate hypertriglyceridemia on a chow diet, developed severe hypertriglyceridemia on high-carbohydrate feeding or aging as seen in patients with human apo AV deficiency. These responses were nearly completely abolished in the Apoa5−/−;Srebp-1c−/− mice. Further mechanistic studies revealed that in response to these environmental factors, SREBP-1c was activated to increase triglyceride synthesis and to permit the incorporation of triglyceride into abnormally large-VLDL particles, which require apo AV for efficient clearance. Conclusions— Severe hypertriglyceridemia develops only when genetic factors (apo AV deficiency) and environmental effects (SREBP-1c activation) coexist. We demonstrate that the regulated production of large-sized VLDL particles via SREBP-1c determines plasma triglyceride levels in apo AV deficiency. Our findings explain the long-standing enigma of the late-onset hypertriglyceridemia phenotype of apo AV deficiency and suggest a new approach to treat hypertriglyceridemia by targeting genes that mediate environmental effects.

[1]  M. Nagano,et al.  A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration Published, JLR Papers in Press, June 16, 2005. DOI 10.1194/jlr.D500018-JLR200 , 2005, Journal of Lipid Research.

[2]  Päivi Pajukanta,et al.  Association of the APOLIPOPROTEIN A1/C3/A4/A5 Gene Cluster With Triglyceride Levels and LDL Particle Size in Familial Combined Hyperlipidemia , 2004, Circulation research.

[3]  Toshiko Tanaka,et al.  Two independent apolipoprotein A5 haplotypes modulate postprandial lipoprotein metabolism in a healthy Caucasian population. , 2007, The Journal of clinical endocrinology and metabolism.

[4]  J. Goldstein,et al.  Selective versus total insulin resistance: a pathogenic paradox. , 2008, Cell metabolism.

[5]  S. Young,et al.  Intravenous Injection of Apolipoprotein A-V Reconstituted High-Density Lipoprotein Decreases Hypertriglyceridemia in apoav−/− Mice and Requires Glycosylphosphatidylinositol-Anchored High-Density Lipoprotein–Binding Protein 1 , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[6]  D. Steinberg,et al.  Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins. , 1980, The American journal of physiology.

[7]  P. Nilsson-ehle,et al.  A stable, radioactive substrate emulsion for assay of lipoprotein lipase. , 1976, Journal of lipid research.

[8]  G. S. Shelness,et al.  Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion[S] , 2011, Journal of Lipid Research.

[9]  Tanya M. Teslovich,et al.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.

[10]  Y. Yazaki,et al.  Heterogeneous mutations in the human lipoprotein lipase gene in patients with familial lipoprotein lipase deficiency. , 1991, The Journal of clinical investigation.

[11]  S. Young,et al.  The Acidic Domain of GPIHBP1 Is Important for the Binding of Lipoprotein Lipase and Chylomicrons* , 2008, Journal of Biological Chemistry.

[12]  J. H. Lee,et al.  Comparison of Low-Fat Meal and High-Fat Meal on Postprandial Lipemic Response in Non-Obese Men according to the −1131T>C Polymorphism of the Apolipoprotein A5 (APOA5) Gene (Randomized Cross-Over Design) , 2006, Journal of the American College of Nutrition.

[13]  P. Pajukanta,et al.  Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia , 2007, Nature Genetics.

[14]  Martin Adiels,et al.  Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[15]  T. Kadowaki,et al.  Identification of Neutral Cholesterol Ester Hydrolase, a Key Enzyme Removing Cholesterol from Macrophages* , 2008, Journal of Biological Chemistry.

[16]  M. Brown,et al.  Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. , 1999, The Journal of clinical investigation.

[17]  J. Esko,et al.  Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. , 2013, The Journal of clinical investigation.

[18]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[19]  R. Hammer,et al.  Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice[S] , 2018, Journal of Lipid Research.

[20]  S. Young,et al.  Abnormal Patterns of Lipoprotein Lipase Release into the Plasma in GPIHBP1-deficient Mice* , 2008, Journal of Biological Chemistry.

[21]  P. Reitsma,et al.  Apolipoprotein A-V , 2001, The Journal of Biological Chemistry.

[22]  A. Khera,et al.  Genetics of coronary artery disease: discovery, biology and clinical translation , 2017, Nature Reviews Genetics.

[23]  R. Zechner,et al.  Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. , 1995, The Journal of clinical investigation.

[24]  I. Sakata,et al.  Role of Hormone-sensitive Lipase in Leptin-Promoted Fat Loss and Glucose Lowering , 2017, Journal of atherosclerosis and thrombosis.

[25]  S. Grundy,et al.  Dual defect in metabolism of very-low-density lipoprotein triglycerides. Patients with type 5 hyperlipoproteinemia. , 1984, JAMA.

[26]  J. Heeren,et al.  Give me A5 for lipoprotein hydrolysis! , 2005, The Journal of clinical investigation.

[27]  J. Polonovski,et al.  [Structure and metabolism of plasma lipoproteins]. , 1983, Pathologie-biologie.

[28]  L. Pennacchio,et al.  Apolipoprotein A-V Deficiency Results in Marked Hypertriglyceridemia Attributable to Decreased Lipolysis of Triglyceride-Rich Lipoproteins and Removal of Their Remnants , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[29]  R. Hammer,et al.  Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. , 1998, The Journal of clinical investigation.

[30]  Folkert Kuipers,et al.  Stimulation of Lipogenesis by Pharmacological Activation of the Liver X Receptor Leads to Production of Large, Triglyceride-rich Very Low Density Lipoprotein Particles* , 2002, The Journal of Biological Chemistry.

[31]  B. Staels,et al.  Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia , 2008, Circulation research.

[32]  M. Foretz,et al.  Sterol-regulatory-element-binding protein 1c mediates insulin action on hepatic gene expression. , 2001, Biochemical Society transactions.

[33]  Andrew D. Johnson,et al.  Multiple rare alleles at LDLR and APOA5 confer risk for early-onset myocardial infarction , 2014, Nature.

[34]  L. Pennacchio,et al.  Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. , 2005, The Journal of clinical investigation.

[35]  D. Porte,et al.  Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. , 1973, The Journal of clinical investigation.

[36]  R. Hammer,et al.  Diminished Hepatic Response to Fasting/Refeeding and Liver X Receptor Agonists in Mice with Selective Deficiency of Sterol Regulatory Element-binding Protein-1c* , 2002, The Journal of Biological Chemistry.

[37]  A. Cantafora,et al.  Inherited Apolipoprotein A-V Deficiency in Severe Hypertriglyceridemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[38]  A. Boodhoo,et al.  The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. , 2005, Clinical chemistry.

[39]  K. Wenner,et al.  Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant. , 2014, Atherosclerosis.

[40]  Rick B. Vega,et al.  CAT‐2003: A novel sterol regulatory element‐binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3‐Leiden mice , 2017, Hepatology communications.

[41]  H. Sone,et al.  Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. , 2004, Diabetes.

[42]  B. Nordestgaard Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.

[43]  S. Nilsson,et al.  Apolipoprotein A-V-heparin Interactions , 2005, Journal of Biological Chemistry.

[44]  M. S. Brown,et al.  Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Yamashita,et al.  Identification of Unique Lipoprotein Subclasses for Visceral Obesity by Component Analysis of Cholesterol Profile in High-Performance Liquid Chromatography , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[46]  Päivi Pajukanta,et al.  Association of the APOLIPOPROTEIN A 1 / C 3 / A 4 / A 5 Gene Cluster With Triglyceride Levels and LDL Particle Size in Familial Combined Hyperlipidemia , 2004 .

[47]  Robert V Farese,et al.  Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. , 2012, Cell metabolism.

[48]  T. Kadowaki,et al.  Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver Published, JLR Papers in Press, June 1, 2006. , 2006, Journal of Lipid Research.

[49]  K. Adeli,et al.  Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. , 2010, American journal of physiology. Endocrinology and metabolism.

[50]  R. Hegele,et al.  Chylomicronaemia—current diagnosis and future therapies , 2015, Nature Reviews Endocrinology.

[51]  A. Remaley,et al.  Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[52]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[53]  S. Young,et al.  Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. , 2007, Cell metabolism.

[54]  D. Nickerson,et al.  Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. , 2004, Biochimica et biophysica acta.

[55]  R. Krauss,et al.  Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. , 1993, The Journal of clinical investigation.

[56]  P. Talmud Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review. , 2007, Atherosclerosis.

[57]  T. Forte,et al.  Apolipoprotein A-V gene therapy for disease prevention / treatment: a critical analysis , 2015, Journal of biomedical research.

[58]  L. Pennacchio,et al.  Apolipoprotein AV Accelerates Plasma Hydrolysis of Triglyceriderich Lipoproteins by Interaction with Proteoglycan-bound Lipoprotein Lipase* , 2005, Journal of Biological Chemistry.

[59]  Joseph L Goldstein,et al.  LXR-SREBP-1c-Phospholipid Transfer Protein Axis Controls Very Low Density Lipoprotein (VLDL) Particle Size* , 2009, The Journal of Biological Chemistry.

[60]  Exome sequencing identifies rare LDLR and APOA 5 alleles conferring risk for myocardial infarction , 2016 .

[61]  T. Forte,et al.  Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice Published, JLR Papers in Press, December 3, 2007. , 2008, Journal of Lipid Research.